Browse Articles

Discover research articles across all indexed journals

Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers.

Journal of Clinical Oncology Todd A. Hembrough, Poorva Mudgal, Zachary Opheim et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.262

262 Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, and early detection is critical for successful treatment and improved survival rates. However, precancerous and early-stage CRC present significant diagnostic challenges due to the small size of lesions and the very low expression of tumor-specific biomarkers in the bloodstream. Current genomics-based diagnostic methods struggle to detect these early-stage and precancerous lesions, making it imperative to develop more sensitive and specific approaches. Circulating extracellular vesicles (EVs) are emerging as a promising solution for early-stage CRC detection. Since EVs are produced by tumor cells as well as tumor microenvironment and host immune response cells, EVs offer the means to detect and monitor small early-stage tumors through both direct detection of tumor-associated biomarkers as well as tumor specific host response and tumor microenvironment biomarkers. Methods: To identify novel early-stage CRC specific biomarkers, we performed proteomics analysis on EVs purified from patient plasma using size exclusion chromatography and a proprietary buffer system that enhances EV and corona protein recovery. TrueDiscovery Data-independent acquisition (DIA) mass spectrometry (MS) analysis was conducted on 24 pre-cancer/stage 0 and 25 stage 1 CRC patients and 75 normal patient plasma samples. An in-house developed machine learning pipeline was used to identify differentially expressed proteins and model candidate multiplexes to identify those with extremely high diagnostic accuracy (> 0.99). Results: An average of ~2,500 proteins were identified per sample and included in bioinformatics analysis. Comparative analysis between control patient EVs and either pre-cancerous/Stage 0, or Stage 1 colon cancer EVs using an in-house Machine Learning pipeline identified 336 and 493 differentially expressed proteins for each group (FDR adjusted p-value < 0.001). Of these, the best 17 pre/stage 0 proteins and 53 stage 1 proteins were trained and tested using Support Vector Machine to assess all potential 3-plexes in order to identify those with mean diagnostic accuracy > 99%. This yielded 5 3-plexes in precancer/stage 0 and 34 3-plexes in stage 1 with near perfect diagnostic accuracy. These plexes are currently being assessed in single analyte and multiplex immunoassays with the goal of translating candidate 3-plexes to the clinical. Conclusions: Key biomarkers from CRC patient EVs indicate the potential to detect and diagnose early-stage and low tumor burden cancers using our methods. Interestingly, the most accurate 3-plexes consist of proteins from immune, inflammatory and metabolic processes, suggesting that for the detection of early stage cancer it may be critical to include both tumor and host specific biomarkers.

Transition of Perovskite Solar Technologies to Being Flexible

Advanced Materials Luigi Angelo Castriotta, Md Aslam Uddin, Haoyang Jiao et al. Feb 01, 2025 DOI: 10.1002/adma.202408036

Abstract Perovskite technologies has taken giant steps on its advances in only a decade time, from fundamental science to device engineering. The possibility to exploit this technology on a thin flexible substrate gives an unbeatable power to weight ratio compares to similar photovoltaic systems, opening new possibilities and new integration concepts, going from building integrated and applied photovoltaics (BIPV, BAPV) to internet of things (IoT). In this perspective, the recent progress of perovskite solar technologies on flexible substrates are summarized, focusing on the challenges that researchers face upon using flexible substrates. A dig into material science is necessary to understand what kind of mechanisms are limiting its efficiency compare to rigid substrates, and which physical mechanism limits the upscaling on flexible substrate. Furthermore, an overview of stability test on flexible modules will be described, suggesting common standard procedure and guidelines to follow, showing additional issues that flexible modules face upon bending, and how to prevent device degradation providing an ad‐hoc encapsulation. Finally, the recent advances of flexible devices in the perovskite market will be shown, giving an outline of how this technology is exploited on flexible substrates, and what are still missing that need stakeholders’ attention.

Genetic differences in colorectal cancer across race and ethnicity.

Journal of Clinical Oncology Carrie Sha, Zhengming Chen, Fatima Qadri et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.28

28 Background: Colorectal cancer (CRC) is the fourth most common cause of cancer death and cancer-related mortality is expected to increase exponentially. Ethnic minorities, in particular African Americans, have increased mortality from CRC. Although multifactorial, differences in somatic gene mutations could contribute to these racial discrepancies. Mutations in the critical oncogene KRAS are associated with worse prognosis in CRC. Recent literature suggests that in CRC patients, KRAS mutations are more frequently found in African Americans compared to Caucasians. This finding led to our hypothesis that molecular alterations across multiple races/ethnicities could explain differences in patient outcomes. This project will also inform a larger analysis using artificial intelligence learning models to predict race from tumor-specific genetic variants, as a tool to identify genetic drivers of race-specific patient outcome. Methods: We examined the molecular alterations in 304 patients diagnosed with CRC who had genetic testing between June 2021 and April 2023 at NYP Queens, NYP Brooklyn, and NYP Cornell. Race and ethnicity, genetic mutations, mortality, tumor location, and age, stage, and the presence of metastasis at diagnosis was collected. Patients self-identified as Non-Hispanic Black (NHB), White (NHW), Asian (NHA), American Indian (NHAI), or Hispanic, Other, or Declined. Median and interquartile range were used to summarize continuous variables, and frequency and proportion were used to summarize categorical variables. The significance of difference across ethnicity groups was tested using Kruskal-Wallis rank sum test for continuous variables and Fisher’s exact test for categorical variables. Mutational correlates of race using a multiple-instance learning artificial intelligence approach (i.e. Anaya et al., Nature Biomedical Engineering, 2023), will be presented. This method will predict race from patients' tumor-specific genetic variants, allowing us to identify specific variants and patterns predictive of race, and potential drivers of patient outcome. Results: Amongst the 304 CRC patients, we identified 116 NHW, 51 NHA, 40 NHB, 35 Hispanic and 1 NHAI, for a total population of 243. BRAF mutations were almost absent in NHB (2.5%) and NHA (3.9%), compared to NHW (13.8%; p=0.02). KRAS mutations were also more prevalent in underserved populations; 65.7% Hispanic, 57.5% NHB, compared with 44.8% NHW (p=0.14). We further identified substantial differences in KRAS mutations when dividing the Asian population into East Asian (62.9%) and South Asian (37.5%). Conclusions: We identified significant differences in key molecular drivers between ethnicities. Our findings suggest that genomic and tumor specific differences across ethnicities could in part explain differences in patient survival across these groups. Mutational correlates of race and survival using natural language processing will be presented.

Use of pathological response versus RECIST assessment in predicting relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.

Journal of Clinical Oncology Antonio D'Alessio, Pasquale Lombardi, Bernardo Stefanini et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.633

633 Background: Immune checkpoint inhibitors (ICI) administered prior to liver resection (LR) lead to pathological responses in patients with hepatocellular carcinoma (HCC). However, the relative value of pathological versus radiological response in predicting relapse-free survival (RFS) remains unclear. Methods: We pooled patient-level data from 111 patients (pts) with HCC receiving ICI prior to LR as part of 5 phase I/II trials and observational clinical studies conducted in 12 centres in the United States, United Kingdom and Asia, as part of an academic consortium (NeoHCC). Pathological response was measured as the percentage of non-viable tumour in the resected specimen, with major (pMR) and complete pathological response (pCR) corresponding to ≥70% and 100% tumour regression. Radiological overall response rate (ORR) was assessed by RECIST v1.1 and modified RECIST (mRECIST) criteria. We correlated pathological response and ORR with RFS using Cox regression. Results: Pts received preoperative ICI between Oct 5, 2017, and Nov 15, 2023, mostly ICI combinations (69%, n=76). Most pts were male (78%, n=87) with viral chronic liver disease (66%, n=73), BCLC stage A HCC (55%, n=61). ORR was 28% per RECIST v1.1 and 32% per mRECIST criteria (available for n=81). Out of the 104 pathologically evaluable pts, pMR and pCR rates were 32% (n=33) and 18% (n=19). Radiological response by RECIST v1.1 showed a significant correlation with pathological response (R 2 = 0.43, p<0.001). When using RECIST v1.1, 74% of pts with ORR achieved pMR vs 14% of those without ORR (n=23/31 vs 10/73, p<0.001). However, 30% of pMR were not predicted by ORR (n=10/33). The discrepancy between pMR and ORR decreased using mRECIST. ORR per mRECIST was 83% in pMR pts (n=19/23), whereas it was 10% in non-pMR (n=5/51). After a median follow-up of 27.2 mos (95%CI 22.3-32.1), median RFS for the whole cohort was 43.6 mos (95%CI 28.3-NE). Achievement of pMR, pCR and ORR was associated with improved RFS (Table). However, reduction in the risk of relapse and/or death was higher in pts achieving pMR or pCR than ORR, regardless of the use of RECIST v1.1 or mRECIST. Conversely, pts without pMR had a lower mRFS than pts without ORR (28.3 mos [95%CI 12.8-43.8] and 32.8 mos [95%CI 13.7-51.9], respectively). Conclusions: Whilst radiological responses to neoadjuvant ICI are associated with improved RFS in pts with HCC, achievement of pMR is more accurate than RECIST and mRECIST-based responses in predicting for RFS, with lack of pMR identifying pts at a higher risk of relapse or mortality. Cox regression for RFS HR (95% CI) p value pCR 0.19 (0.05-0.78) 0.02 pMR 0.25 (0.10-0.66) 0.005 RECIST 1.1 0.34 (0.13-0.86) 0.02 mRECIST 0.38 (0.13-1.11) 0.08 RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; pCR, complete pathological response; pMR, major pathological response; mRECIST, modified RECIST.

Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial.

Journal of Clinical Oncology Fengpeng Wu, Linlin Xiao, Chaoxi Zhou et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.150

150 Background: It has been found that radiotherapy possess synergistic anticancer effect with immune checkpoint inhibitors (ICIs). Therefore, this phase II randomized clinical trial (RCT) (ClinicalTrials.gov identifier: NCT05086627) aimed to evaluate the efficacy and safety of SCRT followed by CAPOX and tislelizumab in patients with LARC. Methods: Patients initially diagnosed rectal adenocarcinoma with cT1-2N+M0 or cT3-4NanyM0 were recruited, randomly assigned to receive SCRT (25Gy/5f), followed by four cycles of CAPOX combined with tislelizumab or CAPOX alone, respectively. After total mesorectal excision (TME), two cycles of postoperative adjuvant chemotherapy were given according to the patient's preferences. The pCR rate was set as the primary endpoint, and the major pathological response (MPR) (tumor regression grade (TRG) 0+1), 3-year progression free survival (PFS), 3-year overall survival (OS) and treatment safety were set as the secondary endpoints. R esults: Between September 2021 and March 2024, 118 patients were randomly assigned and 111 patients started allocated treatment, with 53 in the trial group and 58 in the control group. Ninety-six patients (86.5%) completed SCRT and 4 cycles of CAPOX chemotherapy with/without tislelizumab, including 49 patients (92.5%, 49/53) in the trial group and 47 patients (81.0%, 47/58) in the control group. Eighty-two patients (85.4%) had surgical resection, including 42 patients (85.7%, 42/49) in the trial group and 40 patients (85.1%, 40/47) in the control group. Among 82 patients who underwent surgery, 54.8% (23/42) patients in the trial group achieved pCR compared with 37.5% (15/40) in the control group. During the neoadjuvant treatment period, the incidence of grade 3-4 AEs were 9.4% in the trial group and 10.3% in the control group. Conclusions: SCRT-based TNT combined with tislelizumab followed by TME exhibited a favorable pCR rate in LARC. Clinical trial information: NCT05086627 . Surgical and postoperative pathological outcomes. Characteristic Experimental group (n= 42 ) Control group (n=4 0 ) R0 resection Yes 42 (100%) 40 (100%) No 0 (0%) 0 (0%) pCR Yes 23 (54.8%) 15 (37.5%) No 19 (45.2%) 25 (62.5%) TRG score 0 23 (54.8%) 15 (37.5%) 1 3 (7.1%) 2 (5%) 2 14 (33.3%) 15 (37.5%) 3 2 (4.8%) 8 (20%) Pathological T stage T0 24 (57.1%) 15 (37.5%) Tis 1 (2.4%) 0 (0%) T1 0 (0%) 1 (2.5%) T2 9 (21.4%) 6 (15%) T3 6 (14.3%) 10 (25%) T4 2 (4.8%) 8 (20%) Pathological N stage N0 39 (92.9%) 36 (90%) N1 3 (7.5%) 3 (7.5%) N2 0 (0%) 1 (2.5%) Type of surgery Anterior resection 36 (85.7%) 24 (60%) Abdominoperineal resection 6 (14.3%) 13 (32.5%) Hartmann procedure 0 (0%) 3 (7.5%) Anus preservation Yes 36 (85.7%) 27 (67.5%) No 6 (14.3%) 13 (32.5%)

Effects of neighborhood deprivation index on survival in gastric cancers.

Journal of Clinical Oncology Sawyer Bawek, Mrinalini Ramesh, Kayla Catalfamo et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.336

336 Background: Previous studies have shown that living in disadvantaged neighborhoods resulted in poor outcomes in several malignancies. Neighborhood Deprivation Index (NDI) identifies key variables from 13 measures, including the following dimensions of socioeconomic (SES) status: wealth and income, education, occupation, and housing conditions. In this study, we aimed to investigate the effect of NDI among patients with gastric cancer (GC). Methods: We conducted a retrospective analysis using the Surveillance, Epidemiology, and End Results (SEER) database from 1996-2015. NDI was divided into two groups: less disadvantaged areas (NDI <60) and highly disadvantaged areas (NDI >60), respectively. Demographic and clinical characteristics were summarized by NDI groups. All associations were compared using Kruskal-Wallis and Chi-Square tests, respectively. Kaplan Meier curves were summarized by the NDI group for overall survival (OS) and disease-specific survival (DSS). All associations were compared using a log-rank test. Cox multivariate regression was performed to measure the association between NDI and OS/DSS. All analyses were conducted in RStudio v4.2.3 at a significance level of ≤ 0.05. Results: A total of 19,205 GC (11,137 patients with NDI<60 and 8,068 NDI>60) patients were analyzed. Disadvantaged areas (NDI>60) had a higher proportion of Black and Hispanic, single, uninsured, rural patients with later disease stage as compared to NDI <60. Median OS was 10.0 months for patients with NDI <60 versus 9.0 months for those with NDI >60 (p=0.0007). Median DSS was 12.0 months for NDI <60 and 10.0 months for NDI >60 (p=0.010). Multivariate analysis revealed that factors associated with worse OS included NDI >60 [HR 1.044, p=0.009], age (>60) [HR 1.28, p<0.001], male sex [HR 1.082, p<0.001], single marital status [HR 1.21, p<0.001], uninsured status [HR 1.13], p <0.001], advanced disease stage (III/IV) [HR 2.05, p<0.001], and higher grade [HR 1.32, p<0.001]. On the other hand, non-Hispanic Black [HR 0.98] and Hispanic [HR 0.94] race and urban location [HR 0.91, p<0.001] were associated with improved OS. Factors associated with inferior DSS included NDI >60 [HR 1.037, p=0.038], age (p<0.001), male sex [HR 1.05, p=0.005], single marital status [HR 1.15, p<0.001], advanced disease stage (III/IV) [HR 2.375, p<0.001], and advanced grade (III/IV) [HR 1.40, p<0.001). In contrast, Hispanic [HR 0.94], non-Hispanic Black [0.96], and urban location [HR 0.90, p<0.001] were associated with improved DSS. Conclusions: Patients from areas with higher NDI had worse OS and DSS for GC. Tailored healthcare policies that aim to improve healthcare delivery to areas with high deprivation may help improve GC outcomes.

Short- and long-term outcomes of conversion surgery for initially unresectable advanced gastric cancer: A Japanese multicenter retrospective cohort study.

Journal of Clinical Oncology Itaru Yasufuku, Masanori Terashima, Naoki Takahashi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.402

402 Background: The efficacy of conversion surgery in patients with unresectable advanced gastric cancer at the initial diagnosis who converted to be resectable due to remarkable response to chemotherapy is unclear. To evaluate short- and long-term outcomes of conversion surgery for initially unresectable cStage IVB/pStage IV gastric cancer as the basic data for the JCOG2301 trial, which is a randomized controlled trial comparing conversion surgery with continuation of chemotherapy, a multicenter retrospective cohort study was conducted in the Stomach Cancer Study Group of the Japan Clinical Oncology Group. Methods: Inclusion criteria were as follows; (1)gastric cancer with at least one of following distant metastasis at the initial diagnosis; (i) peritoneal metastasis (PER) diagnosed by imaging examination or P1b or P1c disease diagnosed by laparoscopy or laparotomy, (ii) multiple liver metastasis (HEP) more than three lesions, and (iii) distant lymph node metastasis (LYM) beyond paraaortic lymph node station 16a2/b1, (2) conversion to be resectable after systemic chemotherapy, (3) surgery aiming at an R0 resection of the primary and remaining lesions between April 2010 and September 2017. Clinical data were retrospectively obtained from electronic patient records of 58 institutions. Results: Atotal of 241 patients were included to the study. Initial unresectable factors were PER, HEP, and LYM in 132(55%), 37(15%), and 63(26%) patients, respectively, and 9(4%) patients had two or more factors. Conversion to be resectable obtained during the first and second/later line chemotherapy was in 209 (87%) patients and 32 (13%), respectively. 182(76%), 29(12%), and 30(12%) patients underwent R0, R1, and R2 resection, respectively. The incidence of postoperative complication of Clavien-Dindo Grade II or higher was 24% and no surgery-related death was observed. The median overall survival (mOS) from surgery was 45.4 (95%CI 30.9-61.4) months in R0 resection, 16.6 (11.5-18.5) months in R1, and 20.9 (11.3-35.6) months in R2. In case of R0 resection, the mOS from surgery was 34.4 (95%CI 26.5-59.2) months in PER, 55.9 (21.8-96.7) months in HEP, 54.6 (30.9-98.3) months in LYM, and not reached (19.7-NA) in two or more factors. Conclusions: Conversion surgery appears to be safe and a promising treatment strategy for patients who have initially unresectable advanced gastric cancer and presented remarkable response to systemic chemotherapy.

Effect of changes in body composition and sociodemographic factors on colon cancer survival.

Journal of Clinical Oncology Ignacio Catala Vilaplana, Gillian V.H. Smith, Hannah K. Schulte et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.296

296 Background: Muscle mass, muscle quality, and adipose tissue volumes have been shown to affect colon cancer survival. Further research is required to understand how change in body composition during treatment impacts colon cancer outcomes, and how covariables such mental health and socioeconomic status affect this relationship. The aim of this project was to examine how changes in body composition during chemotherapy for colon cancer impact the duration of disease-free survival (DFS) and how sociodemographic covariables (age, sex, social isolation, depression, anxiety, income, community size) influence this relationship. Methods: Computed tomography (CT) scans from the time of diagnosis and the end of chemotherapy were obtained from individuals treated for stage III colon cancer with oxaliplatin at BC Cancer between 2012 and 2016. Whole body tissue volumes were estimated based on CT images at the level of the third lumbar vertebra, analysed using DAFS Express (Voronoi Health Analytics Inc., Vancouver BC). Muscle quantity was measured as skeletal muscle index (SMI), and muscle quality was measured as skeletal muscle density (SMD) and skeletal muscle gauge (SMG). Quantity of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), intermuscular adipose tissue (IMAT), and total adipose tissue (TAT) were also measured. Social isolation, anxiety, and depression symptoms were measured using the validated Psychosocial Screen for Cancer–Revised. Neighbourhood income and community population were estimated using postal codes. Cox proportional hazard models were calculated for the effect of body composition variables on DFS, and interactions with sociodemographic variables. Results: Significant reductions in SMI, SMD, SMG, VAT, IMAT and TAT were observed between diagnosis and post-chemotherapy (n=282). Improved survival was associated with higher SMD and lower IMAT at diagnosis and post-chemotherapy, lower VAT at diagnosis, and an increase in VAT or TAT during chemotherapy. Body composition had a more significant effect on survival in individuals who were older, female, or lived in smaller communities. Conclusions: Significant reductions in SMI, SMD, SMG, VAT, IMAT and TAT were observed between diagnosis and post-chemotherapy (n=282). Improved survival was associated with higher SMD and lower IMAT at diagnosis and post-chemotherapy, lower VAT at diagnosis, and an increase in VAT or TAT during chemotherapy. Body composition had a more significant effect on survival in individuals who were older, female, or lived in smaller communities.

Engineering Atom‐Scale Cascade Catalysis via Multi‐Active Site Collaboration for Ampere‐Level CO<sub>2</sub> Electroreduction to C<sub>2+</sub> Products

Advanced Materials Chenghao Jin, Yue Lin, Yanan Wang et al. Feb 01, 2025 DOI: 10.1002/adma.202412658

AbstractElectrochemical reduction of CO2 to value‐added multicarbon (C2+) productions offers an attractive route for renewable energy storage and CO2 utilization, but it remains challenging to achieve high C2+ selectivity at industrial‐level current density. Herein, a Mo1Cu single‐atom alloy (SAA) catalyst is reported that displays a remarkable C2+ Faradaic efficiency of 86.4% under 0.80 A cm−2. Furthermore, the C2+ partial current density over Mo1Cu reaches 1.33 A cm−2 with a Faradaic efficiency surpasses 74.3%. The combination of operando spectroscopy and density functional theory (DFT) indicates the as‐prepared Mo1Cu SAA catalyst enables atom‐scale cascade catalysis via multi‐active site collaboration. The introduced Mo sites promote the H2O dissociation to fabricate active *H, meanwhile, the Cu sites (Cu0) far from Mo atom are active sites for the CO2 activation toward CO. Further, CO and *H are captured by the adjacent Cu sites (Cu&amp;+) near Mo atom, accelerating CO conversion and C─C coupling process. Our findings benefit the design of tandem electrocatalysts at atomic scale for transforming CO2 to multicarbon products under a high conversion rate.

Surufatinib combined with locoregional therapies and immune checkpoint inhibitor (ICI) for treating unresectable or metastatic intrahepatic cholangiocarcinoma.

Journal of Clinical Oncology Wan Guang Zhang, Zhan Guo Zhang, Jian Ping Zhao et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.593

593 Background: Advanced metastatic ICC, characterized by poor survival and limited therapeutic options, may benefit from the combined use of surufatinib—a selective tyrosine kinase inhibitor targeting VEGFR 1, 2, and 3, FGFR1, and CSF-1R—and ICIs, alongside locoregional treatments like TACE, DEB-TACE, and HAIC. Methods: Eligible pts who were 18 -75 years old with histologically confirmed unresectable or metastatic intrahepatic cholangiocarcinoma were enrolled. Pts received surufatinib (250mg, orally daily), ICI, and locoregional therapies until surgery, disease progression, death, intolerable toxicity, or withdrawal of consent. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), disease control rate (DCR), overall survival (OS), conversion to surgical resection rate and safety. Results: By July 31, 2024, 20 pts were enrolled and 10 pts were evaluated. Median age was 56.4 years (range: 36-69), with a majority being male (70%). 9 pts were pathologically confirmed as adenocarcinoma, 1patient was small bile tract type. Treatment included DEB-TACE (20%), TACE (30%), and HAIC (50%). 50% (5/10) pts achieved partial response (PR), 20% (2/10) pts accepted conversion surgery, 30% (3/10) pts achieved stable disease (SD), and the confirmed ORR was 50%, DCR was 80%. The median PFS (95%Cl: 6.9-NA months) had not yet matured, with no significant differences in survival benefits based on age or gender, though TACE showed potential benefits. The most common AEs of all grades were nausea (30%), dizziness (30%), and headache (10%), No grade ≥ 3 TEAEs or new safety signals occurred. Conclusions: Surufatinib plus immune checkpoint inhibitor, along with locoregional therapies showed preliminary anti-tumor activity and manageable toxicity for the 1L treatment of ICC, providing an additional treatment option for pts with ICC. Clinical trial information: NCT05236699 .

Clinical outcomes and changes in body composition following endoscopic submucosal dissection versus total gastrectomy in patients with proximal early gastric cancer.

Journal of Clinical Oncology Ga Hee Kim, Hyoung-Il Kim, Sung Hyun Park et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.415

415 Background: Sarcopenia is associated with poor surgical outcomes and prognosis in patients with gastric cancer. However, the relationship between changes in skeletal muscle following endoscopic submucosal dissection (ESD) versus total gastrectomy (TG) in patients with proximal early gastric cancer (EGC) remains unclear. This study aimed to investigate the clinical outcomes and skeletal muscle mass changes between ESD and TG in patients with proximal EGC. Methods: We retrospectively reviewed 329 patients who underwent either ESD (n=127) or TG (n=202) for cT1N0M0 gastric cancer in the upper third of the stomach between 2015 and 2019 at a tertiary care center. The skeletal muscle index (SMI), visceral/subcutaneous fat, and abdominal circumference were measured preoperatively, and at 1 and 3 years after surgery, using cross-sectional computed tomography. We compared these parameters between the two groups and assessed both short- and long-term outcomes, as well as prognostic factors. Results: No significant differences were observed between the two groups with respect to overall survival (P=0.266), recurrence-free survival (P=0.079), or disease-specific survival (P=0.24). The recurrence rate was four (3.1%) in the ESD group and two (0.9%) in the TG group. Of the four recurrences in the ESD group, two were cured by gastrectomy, and two by ESD. Two recurrences in the TG group died of cancer progression. In the ESD group, all deaths were unrelated to gastric cancer, compared to 83.3% in the TG group (P=0.376). Patients in the ESD group showed more preserved SMI (P&lt;0.001), visceral/subcutaneous fat (P&lt;0.001), and abdominal circumference (P&lt;0.001) at 1 and 3 years after surgery, compared to the TG group. The incidence of sarcopenia was significantly lower in the ESD group at postoperative years 1 (22.2% vs. 34.7%, P=0.02) and years 3 (25.7% vs. 40.6%, P=0.001). Sarcopenia had a significant impact on survival, with 5-year OS rates being lower in patients with preoperative sarcopenia (85.3% vs. 95.6%, P=0.005). Multivariate analysis revealed that the prognostic nutritional index was significantly associated with OS (hazard ratio, 0.86; 95% confidence interval: 0.75–0.99, P=0.03). Conclusions: Although OS was comparable between the ESD and TG groups, ESD was associated with better preservation of skeletal muscle and visceral/subcutaneous fat. These results suggest that ESD should be considered for patients with proximal EGC who are at high risk for sarcopenia.

Real-world microscopic residual disease (MRD) monitoring with circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology Peter Chi-Win Li, Harrison David Winters, Xue Geng et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.696

696 Background: ctDNA is a powerful tool that can detect MRD with limited but emerging data in patients (pts) with PDAC. We describe the clinical outcomes of pts with PDAC who underwent real-world MRD testing at our institutions. Methods: We retrospectively analyzed pts at 2 institutions with ≥1 tumor-informed ctDNA test (Natera, Inc) ordered for MRD testing post-operation (post-op) between June 2020-August 2024. Descriptive statistics were used to characterize clinicopathologic factors, ctDNA positivity (ctDNA+), and relapse rates (RR). Median relapse-free survival (mRFS) and overall survival (mOS) were calculated using Kaplan-Meier methods, comparisons between groups by log-rank test, and hazard ratios (HR) by Cox proportional hazard models. Associations between clinicopathologic factors and outcomes were assessed by Fisher’s exact and Chi-square tests. Results: Of the 54 pts who underwent MRD testing, 48 pts (88.9%) had successful tests. Failures were due to insufficient tissue. Patients with successful tests were staged as follows: 31.2% stage 1, 50.0% stage 2, and 18.8% stage 3, with 12.5% having R1/2 resections and 46.8% being node-positive. With a median follow-up of 21.0 months (mo), 22 (45.8%) pts had relapsed and 22 (45.8%) were anytime-ctDNA+. Sensitivity and specificity of ctDNA for relapse was 77.3% and 86.4%, respectively. Between anytime- and never-ctDNA+ pts, RR were 77.0% vs. 23.1%, mRFS 14.2 mo vs. not reached (NR) (HR 4.9, 95% CI 1.9-12.9), and mOS 31.7 mo vs. NR (HR 3.3, 95% CI 1.0-10.9), respectively. For 27 pts tested in the MRD window (2-12 weeks post-op), mRFS was 6.6 vs. 25.0 mo (HR 3.1, 95% CI 1.0-9.4) and mOS was 25.5 mo vs. NR (HR 2.5, 95% CI 0.6-10.2) in ctDNA+ vs. negative pts. ctDNA+ preceded radiographic relapse in 54.5% of patients with a median lead time of 166 days (IQR 70-332). In anytime-ctDNA+ pts, there were non-statistically significant trends for improved RFS and OS based on ctDNA decrease and clearance (table). No clinicopathologic factors predicted ctDNA+. Post-op ctDNA+ (p &lt;0.001) and CA 19-9 (p=0.03) were the only factors that had a significant association with RFS. Conclusions: Post-op ctDNA is a strong prognostic marker for survival in PDAC, predicting relapse about five months before imaging. ctDNA+ status is independent of clinicopathologic factors and the strongest predictor of recurrence. These findings highlight a window where novel therapies could be tested to eradicate MRD. Longer follow up and prospective studies are needed to validate its predictive role with therapies in the MRD setting to improve outcomes in high-risk pts. RFS events/total mRFS (mo) HR (95% CI) p OS events/total mOS (mo) HR (95% CI) p ctDNA clearance Yes 6/9 17.0 0.61 (0.2-1.7) 0.35 2/9 NR 0.37 (0.08-1.8) 0.20 No 11/13 10.3 8/13 31.7 ctDNA MTM/mL reduction ≥50% 8/11 15.5 0.93 (0.3-2.9) 0.90 3/11 NR 0.54 (0.1-2.4) 0.42 &lt;50% 6/8 13.6 4/8 31.7

A Phase‐Transition–Free Sodium Vanadium Phosphate Cathode via Medium‐Entropy Engineering for Superior Sodium Ion Batteries

Advanced Materials Xiao‐Hui Wu, Wei‐Jun Jiang, Chen Dai et al. Feb 01, 2025 DOI: 10.1002/adma.202414358

Abstract Na 3 V 2 (PO 4 ) 3 , based on multi‐electron reactions between V 3+ /V 4+ /V 5+ , is a promising cathode material for SIBs. However, its practical application is hampered by the inferior conductivity, large barrier of V 4+ /V 5+ , and stepwise phase transition. Herein, these issues are addressed by constructing a medium‐entropy material (Na 3.2 V 1.1 Ti 0.2 Al 0.2 Cr 0.2 Mn 0.2 Ni 0.1 (PO 4 ) 3 , ME‐NVP) with strong ME─O bond and highly occupied Na2 sites. Benefiting from the medium‐entropy effect, ME‐NVP manifests a phase‐transition–free reaction mechanism, two reversible plateaus at 3.4 (V 3+ /V 4+ ) and 4.0 V (V 4+ /V 5+ ), and small volume change (2%) during Na + insertion/extraction processes, as confirmed by comprehensive in/ex situ characterizations. Moreover, kinetics analysis illuminates the superior Na + diffusion ability of ME‐NVP. Thus, the ME‐NVP cathode realizes remarkable rate capability of 67 mA h g −1 at 50C and a long‐term lifespan over 10 000 cycles (capacity retention of 81.3%). Theoretical calculations further illustrate that the weak binding of Na + ion in the channel is responsible for the rapid Na + diffusion, accounting for the superior reaction kinetics. Moreover, rigid MEO 6 octahedral and feasible rearrangement of Na + ions can suppress the phase transition, thus endowing an ultrastable ME‐NVP cathode. This work highlights the significant role of medium‐entropy engineering in advancing the output voltage, cycling stability, and rate capability of polyanionic cathodes.

Spatially resolved protein profiling in pancreatic adenosquamous carcinoma.

Journal of Clinical Oncology Adel Kardosh, Rosalie C. Sears, Zheng Xia et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.760

760 Background: Pancreatic adenosquamous carcinoma (PASC) is a rare histopathological type of pancreatic cancer that is more aggressive than pancreatic ductal adenocarcinoma (PDAC). Although PASC has a unique tumor biology and poorer prognosis, there are no guidelines for differentially treating PASC patients, and its rarity makes it significantly understudied. We used Nanostring GeoMX digital spatial profiling (DSP) to provide a targeted proteomic characterization of key tumor-promoting proteins in PASC and PDAC. Methods: FFPE tissue from PASC (n=10 primary, n= 4 met) and PDAC (n=21 primary, n=5 met) cases were analyzed using the DSP platform. Sections were stained with an 82-protein cocktail of antibodies conjugated to UV-photocleavable DNA barcodes. A pan-cytokeratin morphology marker was used to select tumor regions of interest (ROI) and inferred surrounding stromal (i.e., pan-CK negative) ROIs. UV excitation of the defined ROIs was used to release the DNA barcodes and were quantified on the NanoString nCounter system. For PASC, squamous enriched ROI were inferred from corresponding p40 IHC. Corresponding clinical and mutational status for all cases were abstracted from medical records. Results: TP53 (PDAC, 80%; PASC, 83%) and KRAS (PDAC, 76%; PASC, 100%) were the most prevalent mutations . In comparing the tumor ROIs of PASC and PDAC (all cases), DSP-assessed global expression and activation of EGFR-MAPK signaling is significantly increased in PASC, whereas PI3K-AKT signaling is significantly decreased. Compared to PDAC, EGFR expression and phosphorylation (p-EGFR), as well as p-MEK1, are significantly increased in PASC. PASC showed significantly lower levels of PLCG1 and INPP4B, while the majority of other AKT signaling effectors were unchanged. For DNA damage response signaling, PASC showed significantly higher levels of p-ATM, p-CHK2, and p21, but not p-ATR. Likewise, expression of oncoproteins c-MYC and BCL6 were significantly increased in PASC (vs. PDAC). Conclusions: Given that the normal pancreas lacks squamous cells, their histological presence is a uniquely aberrant feature that can be used to guide deep spatially-resolved interrogation of complex cellular and molecular programs. Our preliminary findings show that regions of squamous cell differentiation within PASC have intrinsically higher levels of active EGFR signaling. With emerging RAS-targeted agents poised to alter the treatment landscape, high EGFR signaling in PASC suggest a possible compensatory resistance mechanism that may require additional targeting. Likewise, reliance on ATM signaling highlights this as preferential target for DDR-directed therapies. Building on these results with additional multiomic assays will inform strategies for improving the management of patients with PASC.

Birth cohort effects in appendiceal adenocarcinoma incidence across the United States.

Journal of Clinical Oncology Andreana Natalie Holowatyj, Mary Kay Washington, Richard M Goldberg et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.90

90 Background: Appendiceal adenocarcinoma incidence rates are increasing across all age groups, sexes and histological subtypes in the United States. Birth cohort patterns of appendiceal adenocarcinomas can provide us with new, etiologic clues into these rising rates but have not been examined for this rare malignant tumor type. We estimated appendiceal adenocarcinoma incidence rates across birth cohorts in the United States. Methods: Using the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program data from eight population-based cancer registries, we identified a total of 4,858 persons aged 20+ years when diagnosed with a pathologically-confirmed primary appendiceal adenocarcinoma (non-mucinous, mucinous, goblet cell, signet ring cell carcinoma) between 1975 and 2019. Birth cohorts (1900-1904 to 1990-1994) were created using five-year age groups and time periods. The ratio of age-specific incidence rates was estimated in each birth cohort relative to the 1945-1949 birth cohort and reported as incidence rate ratios (IRRs) with 95% confidence intervals (CI). Results: Compared to persons born in 1945-1949, appendiceal adenocarcinoma incidence rates more than tripled among persons born in 1980-1984 (IRR 3.41, 95%CI 2.54-4.56) and quadrupled among persons born in 1985-1989 (IRR 4.62, 95%CI 3.12-6.82). For all tumor histological types, age-specific appendiceal adenocarcinoma incidence rates increased across successive birth cohorts after 1945-1949—although to varying degrees reported across histological types (e.g., 1980-1984: mucinous adenocarcinoma: IRR 2.71, 95% CI 1.73-4.26; non-mucinous adenocarcinoma: IRR 2.60, 95% CI 1.46-4.63; goblet cell adenocarcinoma: IRR 4.95, 95% CI 2.77-8.85). Conclusions: There are strong, yet distinct birth cohort effects for appendiceal adenocarcinomas across histological subtypes that remain unexplained. These patterns signal that recent exposure changes may be influencing this increasing disease risk for Generation X and Millennials now entering mid-adulthood. With the trend toward more non-operative management of appendicitis, another significant consideration for providers is to keep occult appendiceal tumors in the differential diagnosis of patients who present in this way. The current absence of appendiceal cancer prevention and screening modalities emphasizes the importance of efforts to support earlier detection in a rare malignancy where clinical trials have been historically very limited. Moreover, as similar trends have been reported in other gastrointestinal cancers, this is also suggestive of potential shared exposures contributing to this rising cancer burden across generations.

AMBER part 2F: Cobolimab in combination with dostarlimab in treatment-naïve patients with locally advanced/metastatic and/or unresectable hepatocellular carcinoma (HCC).

Journal of Clinical Oncology Stephen Lam Chan, Benjamin R. Tan, Encarnacion Jimenez et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps650

TPS650 Background: The introduction of targeted treatment (tx) and immune checkpoint inhibitors (ICIs) has transformed the 1L advanced/metastatic (A/M) HCC tx landscape. 1 Combinations of ICIs with anti-angiogenic agents or other ICIs have demonstrated synergism in patients (pts) with A/M HCC, and shown improved efficacy versus single agents or tyrosine kinase inhibitors. 1,2 Combinations with anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and anti-programmed cell death protein-1 (PD-1) ICIs have shown promising anti-tumor activity in pts with solid tumors 3,4 including advanced HCC in US pts. 5 AMBER (NCT02817633) part 2F will evaluate the efficacy and safety of anti-TIM-3 cobolimab plus anti-PD-1 dostarlimab in tx-naïve pts with A/M and/or unresectable HCC. Methods: AMBER is a two-part, global, open-label, Phase Ib study assessing cobolimab as monotherapy or in combination with other drugs in pts with advanced solid tumors. For part 2F, ~45 pts are planned for enrollment. Key eligibility includes pts aged ≥18 years, with Eastern Cooperative Oncology Group (ECOG) performance score 0–1, histologically confirmed A/M HCC with measurable disease, Child-Pugh Class A liver function, no prior systemic tx, documented hepatitis B and C test at screening, and a pre-tx biopsy sample. Eligible pts will receive cobolimab (300 mg IV) plus dostarlimab (500 mg IV) every 3 weeks (Q3W) for up to 2 years or until progression, toxicity, discontinuation, or death. The primary endpoint is investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); secondary endpoints include investigator-assessed disease control rate (DCR), duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1, and overall survival, alpha-fetoprotein response, and safety. Exploratory endpoints include immune-related (ir)-ORR, irDCR, irDOR and irPFS per irRECIST, and biomarker and pharmacokinetic assessments. Disease assessments will consist of CT/MRI evaluations of the chest, abdomen, and pelvis, Q9W from first dose then Q12W after 1 year of tx. Pts will undergo safety follow-up at 30 and 90 (±7) days after last study tx. Efficacy analysis will be based on the safety population (pts who receive ≥1 cobolimab dose) and will include summary statistics and point estimates with 2-sided 95% confidence intervals. Time-to-event analyses will be performed via Kaplan–Meier methods. After ~25 pts have been followed-up for ≥3 scans, an interim analysis may be performed. References: 1. Gordan JD, et al. J Clin Oncol . 2024:42:1830–50; 2. Finn RS, et al. N Engl J Med . 2020;382:1894–1905; 3. Curigliano G, et al. Clin Cancer Res. 2021;27:3620–29; 4. Davar D, et al. J ImmunoTher Cancer . 2023:11(Suppl 1):596; 5. Acoba JD, et al. J Clin Oncol . 2023:41:580. Funding: GSK (213348). Clinical trial information: NCT02817633 .

Gender imbalance in colon cancer screening rates in Texas: A population-based cohort study.

Journal of Clinical Oncology Jorge Rodriguez Vazquez, Ahmed Bashir Sukhera, Gloria Erazo et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.92

92 Background: Males have a higher risk of acquiring Colorectal Cancer (CRC) than females. In Texas, males are diagnosed with CRC more than females, regardless of race or ethnicity. Texas CRC screening compliance rates are lower than the national average of 72.2%. It is important to understand the gender trends in screening to apply more specific strategies. Methods: We used the Texas Outpatient Public Use Data File (TOPUDF), a deidentified and publicly available statewide dataset, to conduct a population-based cohort study of outpatient colon cancer screenings of residents age 45 -74 years old at hospitals and ambulatory surgery centers during 2021. Colon cancer screenings were identified using Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes. We queried the National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER) for age grouped populations in 2021 stratified by gender, race, age group, and county of residence. We calculated age-adjusted outpatient colon cancer screening rates per 100,000 population (AASRs) using the direct standardization method based on the age group weights from the 2000 standard US population. Confidence intervals for AASR were derived by estimating the standard error as the AASR divided by square root of number of colon cancer screenings. The statistical significance of the difference between female and male AASR were tested by comparing the intersection of 95% confidence intervals (95% CI) for the individual rates. Subgroup analyses included age group, rural vs urban residence, and race/ethnicity. Results: A total 514,601 outpatient colon cancer screenings were included in the study of which 275, 189 (53.5%) were for female residents. During 2021, 51.1% of state residents age 45-74 years old were female. The overall statewide AASR in 2021 was 6071.5 (95% CI 6054.6 – 6088.4)) with the female AASR (6282.1 [95% CI 6258.1 – 6306.0]) significantly higher than the male AASR (5847.7 [95% CI 5823.9 – 5871.5]). For residents aged ≥ 45 years the statewide AASR was 5580.8 (95% CI 5565.5 – 5596) with the female AASR (5735.2 [95% CI 5715.9 – 5754.4]) significantly higher than the male AASR (5429.8 [95% CI 5410.1 – 5449.6]). Female residents had higher AASR amongst White, Black, and Hispanic race/ethnicity groups with the largest difference observed for Blacks; female AASR 5843.9 (5777.7 - 5910.1) vs male AASR 4733.5 (4668.5 - 4798.5). The difference between male and female outpatient screening rates was significant among both rural and urban residents. Conclusions: Despite a clear relationship between male gender and CRC, females have a higher rate of colon cancer screening. The Black population has the largest gender difference among race/ethnicity groups.

Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

Journal of Clinical Oncology Zhiwei Chang, Rui-Rui Wang, Xiao-Lei Liu et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.367

367 Background: Recently, PD-1 blockades combined with dual chemotherapy regimens in first-line setting exhibited encouraging efficacy for patients with ESCC. However, the safety profile of conventional dual chemotherapy remained unsatisfactory. Therefore, PD-1 blockades combined with anti-angiogenic tyrosine kinase inhibitors (TKIs) and single chemotherapy regimen might offer a promising strategy. Anlotinib, a novel multitarget TKI primarily targeting VEGFR1-3, demonstrated promising therapeutic activity as first-line combination therapy or second-line monotherapy for ESCC patients in China clinically. Therefore, this study was designed to explore the efficacy and safety of anlotinib combined with penpulimab (PD-1 blockade) and nab-paclitaxel as first-line therapy in advanced ESCC. Methods: Patients with previously untreated metastatic or locally advanced ESCC were recruited and treated with anlotinib (12mg, po, d1~14, q3w) and penpulimab (200mg, iv, d1, q3w) plus nab-paclitaxel (220mg/m 2 , iv, d1, q3w) until disease progression or unacceptable toxicity. The tumor response was assessed according to RECIST 1.1 using CT scans every two cycles. Adverse events were recorded by severity in accordance with the NCI CTC AE Version 5.0. The predefined sample size was 30. Primary endpoint was PFS and secondary endpoints included safety, ORR, DCR and OS. Results: From Jul 2022 to Sep 2024, a total of 30 patients were enrolled, with 29 patients who had received first tumor response were included in this analysis. The best overall response indicated that there were 1 CR (3.4%), 23 PR (79.3%), 2 SD (6.9%) and 3 NE (10.3%). Therefore, the preliminary ORR was 82.8% (95%CI: 64.2%-94.2%), DCR was 89.7% (95%CI: 72.6%-97.8%). The primary median PFS of the 29 patients was 10.84 months (95%CI: 7.57-14.11). Additionally, safety profile exhibited that the regimen was tolerable. The most common treatment-emergent adverse events among the 29 patients with the incidence &gt;20% were anemia (62%), leukopenia (31%), peripheral neurotoxicity (28%) and rash (21%). Common grade ≥3 treatment-emergent adverse events were leukopenia (7%), glutamic-pyruvic transaminase was elevated (3%), glutamic oxalacetic transaminase increased (3%), hypertension (3%), diarrhea (3%) and rash (3%). Conclusions: The combination of anlotinib plus penpulimab and nab-paclitaxel as first-line therapy for advanced ESCC demonstrated promising efficacy and manageable safety profile. And the conclusions needed to be confirmed in subsequent trials. Clinical trial information: ChiCTR2400089133 .

Non-metastatic gastric cancer (GC) in patients aged 80 years or older: Immediate and long-term outcomes of combined treatment.

Journal of Clinical Oncology Nikolay Semenov, Roman Izrailov, Nikita Khodos et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.453

453 Background: Comorbidities and increased risk of chemotherapy-induced toxicity in elderly patients presents significant challenges in management of GC. Here we presents a single-center experience in treatment patients aged 80 years or older with non-metastatic GS, reporting both immediate and long-term outcomes of surgical treatment (ST). Methods: This retrospective analysis includes 61 patients (pts) diagnosed with non-metastatic GC or cardio-esophageal junction (CEJ) cancer. The primary endpoint was relapse-free survival (RFS); secondary endpoints included overall survival (OS) and the incidence of surgical complications (SC). Results: Among the 61 pts (median age 82.7 years, range 80.0-89.2) 39.3% were men. ECOG PS was 0-1 in 49 pts (80.6%) and 2 – in 12 pts (19.4%). The primary tumor site was the stomach in 57 pts (93.4%) and the CEJ in 4 pts (6.6%). Tumor stage had been defined as cT 1-2 in 33.3% pts, cT 3-4 in 57.1%; cN 0 – in 36.1%, stage remained unknown in 6.3%. Radical surgery was performed in pts 78.7% (n=48), 29 pts (47.5%) of them underwent ST only without perioperative chemotherapy (CT). Neoadjuvant CT (NACT) received 23 pts (37.7%): platinum-based doublet regimen – 82.6% (n=19), while 17.4% (n=4) received capecitabine only. ST was performed in 47.8% (n=11) pts received NACT, other 12 pts didn’t undergo ST due to progression of disease (8.3%), comorbidities (33.3%), or patient preference (16.7%) in 1, 4 and 2 cases, respectively. Adjuvant CT was administered to 9 pts (14.3%). Surgical interventions included gastrectomy in 16.6% pts (n=9), proximal or distal resection – in 8.3% (n=4) and 74.1% (n=35), respectively. R0-resection was achieved in 42 pts (88.6%). SC has 20.8% (n=10) pts: classified as Clavien-Dindo grade (G) II – 4.4%, G IIIa – 8.9%, G IIIb - 8.9%; these included anastomotic leakage (6.7%), abscess formation (2.2%), cardiac events and thrombosis (4.4%), and eventration (2.2%). SC G IV or V not reported. The median duration of postoperative hospitalization was 8 days. In the overall cohort, the 3-y RFS was 53% (95%CI 28.9-53.9), 3-y OS – 67% (95%CI 27.9-75.2). Among the pts with stage IA (n=15), the 3-y RFS was 72% (95%CI 49.1-85.1), with a maximum follow-up period of 80 months and no cancer-related deaths. In patients with cT 2-4 N any 3-y RFS was 70% in the overall cohort and 74% in the surgery-only group (HR 1.09; 95%CI 0.45-2.65, p=1). Conclusions: Our findings demonstrate that over 65% of patients aged 80 years or older survive for at least 3 years following surgery for GC, with 53% living without evidence of metastases. Additionally, the rate of SC in this elderly cohort is comparable to that observed in younger populations. The role of perioperative or neoadjuvant CT in this age group remains a topic of ongoing research and discussion. It is critical to manage such population at referral oncological centers with expertise in treating elderly cancer pts.

Proteins that assemble co-translationally lean on their partner for stability

Nature Reviews Molecular Cell Biology Kim Baumann Feb 01, 2025 DOI: 10.1038/s41580-024-00824-x